Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

被引：25
|
作者：
Carlos Hernandez-Boluda, Juan [1 ]
Pereira, Arturo [2 ]
Cervantes, Francisco [3 ]
Gomez, Montse [1 ]
Arellano-Rodrigo, Eduardo [2 ]
Alvarez-Larran, Alberto [4 ]
Ferrer-Marin, Francisca [5 ]
Kerguelen, Ana [6 ]
Antonio Marquez, Jose [7 ]
Luisa Antelo, Maria [8 ]
Besses, Carles [4 ]
机构：
[1] Hosp Clin Univ, Hematol & Med Oncol Dept, Valencia 46010, Spain
[2] Hosp Clin Barcelona, Hemotherapy & Hemostasis Dept, Barcelona, Spain
[3] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Hematol, Barcelona, Spain
[4] Hosp del Mar, Dept Hematol, Barcelona, Spain
[5] Hosp Morales Meseguer, Hematol & Med Oncol Dept, Murcia, Spain
[6] Hosp La Paz, Dept Hematol, Madrid, Spain
[7] Hosp Basurto, Dept Hematol, Bilbao, Spain
[8] Complejo Hosp Navarra, Dept Hematol, Pamplona, Spain
来源：
ANNALS OF HEMATOLOGY | 2013年 / 92卷 / 06期
关键词：
Essential thrombocythemia; Treatment; Anagrelide; Response criteria; POLYCYTHEMIA-VERA; HYDROXYUREA; RECOMMENDATIONS;
D O I：
10.1007/s00277-013-1683-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This study investigates whether the response criteria proposed by the European LeukemiaNet (ELN) to evaluate cytoreductive therapies in essential thrombocythemia (ET) correlate with clinically relevant outcomes in patients receiving anagrelide. We evaluated 154 ET patients treated with anagrelide (upfront in 87) for a median of 2.9 years. Complete response (CR), partial response, and no response were observed in 56, 30.5, and 13.5 % patients, respectively. Only 38 patients (25 %) achieved a sustained CR. Overall, the aggregated time on CR and without CR was 200.1 and 333.6 person-years, respectively. The incidence rate of thrombosis and hemorrhage was independent of the CR status. The only factor associated with shorter survival after anagrelide start was the patient's age, whereas achieving a CR with anagrelide had no predictive value for subsequent survival. In conclusion, CR according to the ELN definition is not associated with any measurable clinical benefit in ET patients treated with anagrelide.
引用
收藏
页码：771 / 775
页数：5
相关论文
共 50 条
  • [21] EFFECT OF ANAGRELIDE ON PLATELET AND ENDOTHELIAL FUNCTION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
    Cacciola, E.
    Di Francesco, E.
    Pezzella, F.
    Tibullo, D.
    Cacciola, R. R.
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (09) : S50 - S50
  • [22] Effects of anagrelide on platelet and fibrinolytic function in patients with essential thrombocythemia
    Cacciola, E.
    Di Francesco, E.
    Giustolisi, R.
    Cacciola, R. R.
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 77 - 77
  • [23] Anagrelide in essential thrombocythemia: A retrospective analysis of 220 patients.
    Gugliotta, L
    Grossi, A
    Mazzucconi, MG
    Bulgarelli, S
    Gamberi, B
    Imovilli, A
    Balestri, F
    Liso, V
    Specchia, G
    Scalzulli, PR
    Liberati, AM
    Bassetti, A
    Angelucci, E
    Di Tucci, A
    Iuliano, F
    Gaidano, G
    Conconi, AR
    Cacciola, E
    Cacciola, R
    Spriano, M
    Crugnola, M
    Tabilio, A
    Balduini, C
    Noris, P
    Amato, B
    Candoni, A
    Balleari, E
    Sacchi, S
    Ambrosetti, A
    Zanotti, R
    Giordano, M
    Andriani, A
    Sciorio, A
    Vasino, AC
    Martinelli, V
    Ciancia, R
    Tringali, S
    Lauria, F
    BLOOD, 2003, 102 (11) : 921A - 921A
  • [24] A toe ulcer in a patient with essential thrombocythemia successfully treated with a combination of anagrelide and prednisolone
    Sugai, Tatsuro
    Yamaguchi, Yasuyuki
    Narahira, Atsushi
    Nohara, Takuma
    Nakamura, Hiroyuki
    Ebata, Ko
    Ujiie, Hideyuki
    DERMATOLOGIC THERAPY, 2022, 35 (02)
  • [25] GATA1 in patients with essential thrombocythemia and anagrelide treatment.
    Rinaldi, Ciro Roberto
    Graham, Ciaren
    Brown, Lillia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Long-term use of anagrelide in young patients with essential thrombocythemia
    Storen, EC
    Tefferi, A
    BLOOD, 2001, 97 (04) : 863 - 866
  • [27] 2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA VALIDATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH 3 AVAILABLE TKIS OUTSIDE CLINICAL TRIALS
    Breccia, M.
    Pregno, P.
    Annunziata, M.
    Orlandi, E.
    Gozzini, A.
    Iurlo, A.
    Bocchia, M.
    Franceschini, L.
    Montefusco, E.
    Crugnola, M.
    La Nasa, G.
    Scortechini, A. R.
    Sgherza, N.
    Sica, S.
    Alimena, G.
    Saglio, G.
    Specchia, G.
    HAEMATOLOGICA, 2016, 101 : 738 - 739
  • [28] THERAPY WITH ANAGRELIDE IN PATIENTS AFFECTED BY ESSENTIAL THROMBOCYTHEMIA - PRELIMINARY-RESULTS
    MAZZUCCONI, MG
    DESANCTIS, V
    CHISTOLINI, A
    DRAGONI, F
    MANDELLI, F
    HAEMATOLOGICA, 1992, 77 (04) : 315 - 317
  • [29] EFFECT OF ANAGRELIDE ON PLATELET, COAGULANT AND ENDOTHELIAL FUNCTION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
    Cacciola, R. R.
    Di Francesco, E.
    Pezzella, F.
    Tibullo, D.
    Cacciola, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 584 - 584
  • [30] MOLECULAR CHARACTERIZATION OF PATIENTS WITH POLYCYTEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA CANDIDATES TO RECEIVE CYTOREDUCTIVE TREATMENT AND ITS RELATIONSHIP WITH THE MOLECULAR RESPONSE ACCORDING TO EUROPEAN LEUKEMIANET
    Fernandez Ibarrondo, L.
    Angona Figueras, A.
    Fernandez Rodriguez, C.
    Camacho Diaz, L.
    Garcia Pallarols, F.
    Garcia Gisbert, N.
    Longaron Rozalen, R.
    Besses Raebel, C.
    Bellosillo Paricio, B.
    HAEMATOLOGICA, 2018, 103 : 70 - 71
12345